The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 10, 2022

Filed:

Mar. 20, 2020
Applicants:

Wjwu & Lynn Institute for Stem Cell Research, Santa Fe Springs, CA (US);

Mello Biotech Taiwan Co., Ltd., Taipei, TW;

Inventors:

Shi-Lung Lin, Arcadia, CA (US);

Samantha Chang-Lin, Arcadia, CA (US);

Chin-Tsyh Donald Chang, Cerritos, CA (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/00 (2006.01); A61K 47/50 (2017.01); A61K 47/51 (2017.01); C12N 15/113 (2010.01); A61K 39/39 (2006.01); A61K 39/29 (2006.01); A61K 39/215 (2006.01); A61P 35/00 (2006.01); A61K 39/21 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 39/21 (2013.01); A61K 39/215 (2013.01); A61K 39/29 (2013.01); A61K 39/292 (2013.01); A61K 39/39 (2013.01); A61P 35/00 (2018.01);
Abstract

This invention generally relates to a group of novel chemical compositions and their use for formulating RNA- and/or DNA-based medicine drugs/vaccines into stable compound complexes useful for both in-vitro and in-vivo delivery. Particularly, the present invention teaches the synthesis of a group of novel trimethylglycyl chemicals and their use for formulating cosmetic, therapeutic- and/or pharmaceutical-grade nucleic acid compositions, including but not limited microRNA precursors (pre-miRNA/miRNA), small hairpin RNAs (shRNA), short interfering RNAs (siRNA), ribozymes, antisense oligonucleotides, RNA-DNA hybrids and DNA-based vectors/vaccines, with or without modification, into delivery complexes, which can then be absorbed by cells in vivo, ex vivo and/or in vitro through an active mechanism of endocytosis via acetylcoline receptors for releasing the therapeutic and pharmaceutical effects of the formulated nucleic acid compositions.


Find Patent Forward Citations

Loading…